US sales of Sanofi/Regeneron's dupilumab for atopic dermatitis could exceed $1.3 billion by 2022, says analyst

4 December 2014

The first biologic to treat atopic dermatitis, French pharma major Sanofi (Euronext: SAN) and US biotech firm Regeneron Pharmaceuticals’(Nasdaq: REGN) dupilumab, could launch in the USA by second-quarter 2017.

Moreover, the potentially game-changing drug could achieve annual sales of over $1.3 billion in this market by 2022, according to an analyst with research and consulting firm GlobalData.

Following impressive top-line Phase IIb safety and efficacy data in moderate-to-severe atopic dermatitis patients in July 2014, dupilumab has been assigned a Breakthrough Therapy designation by the US Food and Drug Administration (The Pharma Letter November 25).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK